June 16, 2010
The FDA has approved GlaxoSmithKline's Jalyn, a fixed dose combination of dutasteride and tamsulosin, for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
June 07, 2010
Amgen announced results from its Phase 3, head-to-head trial that compared denosumab to Zometa (zoledronic acid, from Novartis) in 1,901 patients with bone metastases from hormone-refractory prostate cancer.
May 11, 2010
The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.
March 03, 2010
The FDA has approved a generic version of Flomax (tamsulosin HCl capsules, from Boehringer Ingelheim) for the treatment of benign prostatic hyperplasia (BPH).
January 26, 2010
FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).